Navigation Links
Experimental Drug Eases Symptoms of Mild Alzheimer's
Date:4/30/2008

Tarenflurbil lessened decline in functional ability, British study concludes

WEDNESDAY, April 30 (HealthDay News) -- Patients with mild Alzheimer's disease who took 800 milligrams of the drug tarenflurbil twice a day had less decline in functional ability than those who took a placebo, according to a British phase II trial.

The findings support phase III studies of the drug at this dose, the researchers said. Tarenflurbil reduces production of 42-amino-acid peptide, which is believed to initiate brain damage characteristic of Alzheimer's disease. Previous research had found the drug prevented learning and memory defects in mice with Alzheimer's disease.

In this study, 210 patients were randomly assigned to receive either 400 milligrams of tarenflurbil twice per day (69 patients), 800 milligrams of tarenflurbil twice per day (70 patients), or a placebo (71 patients).

Patients with mild Alzheimer's who took 800 milligrams of tarenflurbil for 24 months had lower rates of decline than those who were in the placebo group for the first 12 months of the study and either tarenflurbil group for the last 12 months of the study.

Common side effects included diarrhea, nausea and dizziness.

The researchers concluded that "800 mg tarenflurbil twice per day was well-tolerated for up to 24 months of treatment, with evidence of a dose-related effect on measures of daily activities and global function in patients with mild AD ... these findings justify phase III studies of tarenfurbil at the 800 mg twice daily dose in patients with mild AD."

The study was published online in The Lancet Neurology.

The findings are sufficient to support Phase III studies of the drug, Dr. Paul Aisen of the University of California, San Diego, wrote in an accompanying commentary.

"With the need so enormous, and the potential effect of the benefit suggested [although not proven] by these phase II results, the effort is indeed justified despite the substantial uncertainty. In a few months, we will learn whether tarenflurbil will be the first anti-amyloid intervention to be efficacious in a pivotal trial," Aisen wrote.

More information

The U.S. National Institute on Aging has more about Alzheimer's disease.



-- Robert Preidt



SOURCE: The Lancet, news release, April 29, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Experimental Blood Substitutes Unsafe, Study Finds
2. Honda to Showcase Experimental Walking Assist Device
3. Experimental Alzheimers Drug Shows Promise
4. Experimental drug shows promise in treating certain lymphomas
5. Experimental Cancer Vaccines Show Promise
6. Gourmetceuticals Presents Findings on Science You Can Eat at Experimental Biology 2008
7. Cavities in Children Reduced Over 60 Percent by New Experimental Chewable Mints
8. Gourmetceuticals to Present Data from Four Studies at Experimental Biology 2008
9. 52 minority scientists receive travel fellowships to Experimental Biology 2008
10. Experimental Biology 2008 Todays Research: Tomorrows Health, April 5-9
11. Experimental Vaccine Halts Prostate Cancer in Mice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... ... Drs. Justin Kolnick, Kara Diamond, Randall Barton, Keith Hope and Bilal Chaudhry ... this treatment plays in protecting oral health, along with the benefits of receiving ... a root canal in White Plains, NY or their second location in Mt. Kisco, ...
(Date:3/27/2017)... ... March 27, 2017 , ... Buzzies parent company, The TouchPoint Solution’s CEO and ... Foundation and UBS’ Project Entrepreneur. Mayo will present her pitch about the lifestyle wearable ... Entrepreneur’s second annual venture competition ignites bold ideas by providing women access to the ...
(Date:3/27/2017)... ... March 27, 2017 , ... Osteitis ... A type of groin injury, it occurs when the muscles around the pelvis ... in and around the lower torso, as well as accompanying tenderness and weakness. ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... nurses and supply chain professionals, will hold their first Northeast Regional AHVAP Meeting. ... Bundles.” , “Increasingly, supply chain and value analysis professionals have a ‘seat ...
(Date:3/27/2017)... , ... March 27, 2017 , ... ... to announce the launch of a months-long rebranding effort. This includes the introduction ... “Through focus group discussions and market research, we learned that a simple, proactive ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... 27, 2017  A new survey from ... Medicare,s Competitive Bidding Program (CBP) significantly reduced beneficiary choice ... lack of choice forces beneficiaries to switch to unfamiliar ... consequences. AADE,s survey is the latest ... others pointing out the inherent problems with the CBP. ...
(Date:3/27/2017)... March 27, 2017 BioLineRx Ltd. (NASDAQ/TASE: ... announced today that AGI-134, an immunotherapy for the treatment of ... Ltd., will be featured at the upcoming American Association ... Washington, DC to be held on April 1-5, ... ...
(Date:3/27/2017)... March 27, 2017  BERG, a biopharmaceutical ... biological research approach, today announced that the ... discovery of new data using a cold-induced ... fat metabolism. Joslin Diabetes Center led the ... platform for analysis of samples.  The findings ...
Breaking Medicine Technology: